logo-annsaudimed

Frequency:


Impact factor: 1.381


Google Scholar h5 Index: 25


Contact:
[email protected]

Disciplines/Subjects/Topics:
Antibody drug conjugates, Fusion toxins and immunotoxins, Nanoparticle therapy, Vascular therapy, Inhibitors of proliferation signaling pathways

Publisher: Mary Ann Liebert, Inc.

Started in: 1984

Journal Language(s): N/A

Has Publiation Charge(s)?:

Publication Charge(s): No Information Available

Keywords: , ,

Publication Medium:

ISSN(Online): 1557-8852

ISSN(Print): 1084-9785

Used Digital Object Identifier (DOI):

Indexed in PubMed:

Availability in HINARI:

Assigned BIOJ: 15-0000069

Country of Publication:

Added to Bioj: 20/05/2015

Homepage: Click here to Enter

Rate this Journal:

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...

Description:


Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.


Leave a Reply